Cassava Leaders Pushed Flawed Alzheimer’s Drug Data, Suit Says

Cassava Sciences Inc.’s top executives and directors touted the efficacy of Alzheimer’s drug candidate Simufilam, despite alleged scientific misconduct that impacted clinical trial data, a shareholder derivative suit says.

The drugmaker’s principal scientific advisor Hoau-Yan Wang was the subject of a citizen petition filed with the US Food and Drug Administration, which called for phase three trials of Simufilam to be paused due to data manipulation. Cassava’s leadership continued to defend Wang and the data from the trials he oversaw, as well as the drug’s efficacy, opening the company up to financial and reputational harm, according to the complaint ...